Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

30.93

Margin Of Safety %

Put/Call OI Ratio

0.59

EPS Next Q Diff

0.27

EPS Last/This Y

-1.05

EPS This/Next Y

0.85

Price

56.09

Target Price

77.21

Analyst Recom

1.97

Performance Q

48.66

Relative Volume

0.97

Beta

1.8

Ticker: CRSP




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04CRSP52.120.560.09150116
2025-07-07CRSP51.250.560.45144835
2025-07-08CRSP54.820.560.33147018
2025-07-09CRSP60.10.580.24149997
2025-07-10CRSP590.610.13152592
2025-07-11CRSP56.810.590.26158146
2025-07-14CRSP56.420.590.50153850
2025-07-15CRSP52.690.600.33159068
2025-07-16CRSP55.150.590.23162766
2025-07-17CRSP55.020.590.41164103
2025-07-18CRSP65.140.600.29164721
2025-07-21CRSP65.260.560.32118990
2025-07-22CRSP65.930.570.43130329
2025-07-23CRSP68.160.580.45133448
2025-07-24CRSP66.110.600.27137128
2025-07-25CRSP64.760.610.44139231
2025-07-28CRSP63.750.630.51129511
2025-07-29CRSP59.040.620.53130595
2025-07-30CRSP57.680.620.22134617
2025-07-31CRSP56.230.610.22138532
2025-08-01CRSP56.110.590.68142010
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04CRSP52.173.5129.4-5.34
2025-07-07CRSP51.183.5144.7-5.34
2025-07-08CRSP54.823.596.4-5.34
2025-07-09CRSP60.083.584.8-5.34
2025-07-10CRSP59.003.5143.5-5.34
2025-07-11CRSP56.803.5161.7-5.34
2025-07-14CRSP56.443.5137.8-5.34
2025-07-15CRSP52.733.5168.1-5.34
2025-07-16CRSP55.143.5110.4-5.34
2025-07-17CRSP55.093.5135.0-5.34
2025-07-18CRSP65.133.540.3-5.34
2025-07-21CRSP65.293.5133.5-5.34
2025-07-22CRSP65.923.5130.3-5.34
2025-07-23CRSP68.143.5118.7-5.34
2025-07-24CRSP66.066.1149.0-5.39
2025-07-25CRSP64.766.1144.0-5.39
2025-07-28CRSP63.836.1141.5-5.39
2025-07-29CRSP59.026.1170.5-5.39
2025-07-30CRSP57.686.1145.9-5.39
2025-07-31CRSP56.266.1147.1-5.39
2025-08-01CRSP56.096.1136.2-5.39
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04CRSP-2.360.2725.86
2025-07-07CRSP-2.360.2425.86
2025-07-08CRSP-2.360.2425.86
2025-07-09CRSP-2.360.2425.86
2025-07-10CRSP-2.360.2425.86
2025-07-11CRSP-2.360.2430.85
2025-07-14CRSP-2.360.2430.85
2025-07-15CRSP-2.360.2430.85
2025-07-16CRSP-2.360.2430.85
2025-07-17CRSP-2.360.2430.85
2025-07-18CRSP33.810.2430.85
2025-07-21CRSP33.810.0431.23
2025-07-22CRSP24.590.0431.23
2025-07-23CRSP24.590.0431.23
2025-07-24CRSP24.590.0431.23
2025-07-25CRSP24.590.0430.93
2025-07-28CRSP24.597.7530.93
2025-07-29CRSP24.597.7530.93
2025-07-30CRSP24.597.7530.93
2025-07-31CRSP24.597.7530.93
2025-08-01CRSP24.597.7530.93
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.58

Avg. EPS Est. Current Quarter

-1.46

Avg. EPS Est. Next Quarter

-1.31

Insider Transactions

24.59

Institutional Transactions

7.75

Beta

1.8

Average Sales Estimate Current Quarter

6

Average Sales Estimate Next Quarter

12

Fair Value

Quality Score

20

Growth Score

37

Sentiment Score

16

Actual DrawDown %

74.5

Max Drawdown 5-Year %

-85.1

Target Price

77.21

P/E

Forward P/E

PEG

P/S

128.59

P/B

2.65

P/Free Cash Flow

EPS

-4.52

Average EPS Est. Cur. Y​

-5.39

EPS Next Y. (Est.)

-4.54

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1023.64

Relative Volume

0.97

Return on Equity vs Sector %

-44.8

Return on Equity vs Industry %

-26.2

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.04

EBIT Estimation

136.2
CRISPR Therapeutics AG
Sector: Healthcare
Industry: Biotechnology
Employees: 393
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
stock quote shares CRSP – CRISPR Therapeutics AG Stock Price stock today
news today CRSP – CRISPR Therapeutics AG stock forecast ,stock prediction 2023 2024 2025
marketwatch CRSP – CRISPR Therapeutics AG yahoo finance google finance
stock history CRSP – CRISPR Therapeutics AG invest stock market
stock prices CRSP premarket after hours
ticker CRSP fair value insiders trading